Drug Most Volatile Stocks: Aerie Pharmaceuticals Inc (NASDAQ:AERI), Biostar Pharmaceuticals (NASDAQ:BSPM), Ventrus Biosciences (NASDAQ:VTUS), Retrophin (NASDAQ:RTRX)

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced that Vicente Anido, Jr., Ph.D., chairman and chief executive officer, will present at the 13th Annual Needham Healthcare Conference on Wednesday, April 9, 2014 at 12:10 pm Eastern Time in New York, NY. Dr. Anido will provide an Aerie overview and business update. Aerie Pharmaceuticals Inc (NASDAQ:AERI) stock performance was -5.36% in last session and finished the day at $21.17. … Continue reading Drug Most Volatile Stocks: Aerie Pharmaceuticals Inc (NASDAQ:AERI), Biostar Pharmaceuticals (NASDAQ:BSPM), Ventrus Biosciences (NASDAQ:VTUS), Retrophin (NASDAQ:RTRX)

Kristen Barton04/0304/03

Healthcare Bearish Stocks: Mediwound (NASDAQ:MDWD), Five Star Quality Care (NYSE:FVE), Ventrus Biosciences (NASDAQ:VTUS), Tonix Pharmaceuticals Holding (NASDAQ:TNXP)

Israeli-based MediWound Ltd (NASDAQ:MDWD) has developed a treatment to remove dead skin from burn wounds, and it has been approved by the European Medicines Agency. Mediwound Ltd (NASDAQ:MDWD) stock performance was -6.88% in last session and finished the day at $14.48. Traded volume was 485.2K shares in the last session and the average volume of the stock remained 1.40million shares. Five Star Quality Care, Inc. … Continue reading Healthcare Bearish Stocks: Mediwound (NASDAQ:MDWD), Five Star Quality Care (NYSE:FVE), Ventrus Biosciences (NASDAQ:VTUS), Tonix Pharmaceuticals Holding (NASDAQ:TNXP)

Colin Pettis03/2803/28

Healthcare Losers: CytRx (NASDAQ:CYTR), Trivascular Technologies (NASDAQ:TRIV), Neuralstem (NYSEMKT:CUR), Ventrus Biosciences Inc (NASDAQ:VTUS)

The company on May 28 announced updated results from its ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas (STS). CytRx Corporation (NASDAQ:CYTR) stock performance was -5.41% in last session and finished the day at $4.02. Traded volume was 9.62million shares … Continue reading Healthcare Losers: CytRx (NASDAQ:CYTR), Trivascular Technologies (NASDAQ:TRIV), Neuralstem (NYSEMKT:CUR), Ventrus Biosciences Inc (NASDAQ:VTUS)

Kristen Barton06/30